ResMed said net revenue for the quarter ended September 30, 2025 was $1,335.6 million, an increase of 9% from $1,224.5 million in the prior-year quarter (8% on a constant currency basis). The company cited increased demand and unit sales as factors for the Sleep and Breathing Health segment increase.

10-QQuarterly reportFiled Oct 31, 2025Period of report Sep 30, 2025Summary published (UTC) Oct 10, 2026

Key points

AI summary

ResMed said net revenue for the quarter ended September 30, 2025 was $1,335.6 million, an increase of 9% from $1,224.5 million in the prior-year quarter (8% on a constant currency basis). The company cited increased demand and unit sales as factors for the Sleep and Breathing Health segment increase.
ResMed said gross margin for the quarter was 61.5% compared to 58.6% in the prior-year quarter, and attributed the increase to manufacturing and logistics efficiencies and component cost improvements. The company recorded restructuring charges of $15.8 million related to workforce planning activities in the quarter, compared to no restructuring expenses in the prior-year quarter.
ResMed said net income for the quarter was $348.5 million, an increase of 12% from $311.4 million in the prior-year quarter, and diluted earnings per share were $2.37 compared to $2.11 in the prior-year quarter. The effective tax rate was 22.0% compared to 18.8% in the prior-year quarter.
ResMed said cash provided by operating activities for the quarter was $457.3 million compared to $325.5 million in the prior-year quarter. The company repurchased 523,212 shares for $150.0 million during the quarter and paid a cash dividend of $0.60 per share ($87.8 million in total).

Key figures

Quarter ended September 30, 2025

Revenue: $1.3B
Operating income: $447M
Net income: $349M
EPS: $2.37
Gross profit: $821M
Operating cash flow: $457M

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Net Revenue for Quarter Ended September 30, 2025: $1,335.6 million

ResMed said net revenue for the quarter ended September 30, 2025 was $1,335.6 million, an increase of 9% from $1,224.5 million in the prior-year quarter (8% on a constant currency basis). The company cited increased demand and unit sales as factors for the Sleep and Breathing Health segment increase.

Source · Based on the MD&A text of the filing

Gross Margin 61.5%; Restructuring Charges $15.8 million

ResMed said gross margin for the quarter was 61.5% compared to 58.6% in the prior-year quarter, and attributed the increase to manufacturing and logistics efficiencies and component cost improvements. The company recorded restructuring charges of $15.8 million related to workforce planning activities in the quarter, compared to no restructuring expenses in the prior-year quarter.

Source · Based on the MD&A text of the filing

Net Income $348.5 million; Diluted Earnings Per Share $2.37

ResMed said net income for the quarter was $348.5 million, an increase of 12% from $311.4 million in the prior-year quarter, and diluted earnings per share were $2.37 compared to $2.11 in the prior-year quarter. The effective tax rate was 22.0% compared to 18.8% in the prior-year quarter.

Source · Based on the MD&A text of the filing

Operating Cash Flow $457.3 million and Share Repurchases

ResMed said cash provided by operating activities for the quarter was $457.3 million compared to $325.5 million in the prior-year quarter. The company repurchased 523,212 shares for $150.0 million during the quarter and paid a cash dividend of $0.60 per share ($87.8 million in total).

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.